Trials / Completed
CompletedNCT04837261
Shortening Duration of Antiarrhythmic Medication for SVT in Infants
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 107 (actual)
- Sponsor
- Tampere University Hospital · Academic / Other
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propranolol | 3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months |
| DRUG | Flecainide | 80 mg/m2/d |
| DRUG | Amiodarone | Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d |
Timeline
- Start date
- 2021-04-15
- Primary completion
- 2024-01-31
- Completion
- 2024-01-31
- First posted
- 2021-04-08
- Last updated
- 2025-11-20
Locations
18 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT04837261. Inclusion in this directory is not an endorsement.